Chacko KR, Wolkoff AW

Language: English
References: 15
Page: 176-178
PDF size: 103.12 Kb.

Text Extraction

Intrahepatic Cholestasis of Pregnancy (ICP) is the most common pregnancy-related liver disease and is characterized by onset of pruritus and elevated serum transaminases and bile acids (BA) in the third trimester of pregnancy. Symptoms and abnormal liver tests resolve following delivery but frequently recur in subsequent pregnancies. Genetic defects of canalicular transporters have been associated with the development of ICP, which may be further influenced by gestational hormones. In particular, the syndrome has been associated in some patients with heterozygosity for mutations in the genes encoding familial intrahepatic cholestasis protein-1 FIC1 (ICP-type 1), bile salt excretory protein (BSEP) (ICP-type 2), and multidrug resistance protein 3 (MDR3) (ICP-type 3). Patients are classified as mild (BA 10-40) or severe (BA › 40) which has implications with respect to the risk of perinatal complications.

REFERENCES

1. Dixon PH, Williamson C. The pathophysiology of intrahepatic cholestasis of pregnancy. Clin Res Hepatol Gastroenterol 2016; 40: 141-53.

2. Keitel V, Dröge C, Stepanow S, Fehm T, Mayatepek E, Köhrer K, Häussinger D. Intrahepatic cholestasis of pregnancy (ICP): case report and review of the literature. Z Gastroenterol 2016; 54: 1327-33.

3. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467-74.

4. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59: 1482-91.

5. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014; 124: 120-33.

6. Jin J, Pan SL, Huang LP, Yu YH, Zhong M, Zhang GW. Risk factors for adverse fetal outcomes among women with early- versus late-onset intrahepatic cholestasis of pregnancy. Int J Gynaecol Obstet 2015; 128: 236-40.

7. Hu Y, Ding YL, Yu L. The impact of intrahepatic cholestasis of pregnancy with hepatitis B virus infection on perinatal outcomes. Ther Clin Risk Manag 2014; 10: 381-5.

8. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43: 723-8.

9. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet Gynecol Clin North Am 2010; 37: 269-82.

10. Walker IA, Nelson-Piercy C, Williamson C. Role of bile acid measurement in pregnancy. Ann Clin Biochem 2002; 39: 105-13.

11. Chen Z, Hu L, Lu M, Shen Z. Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats. Can J Physiol Pharmacol 2016; 94: 402- 7.

12. Abdel-Latif MS. Plasma Levels of Matrix Metalloproteinase (MMP)-2, MMP-9 and Tumor Necrosis Factor-alpha in Chronic Hepatitis C Virus Patients. Open Microbiol J 2015; 9: 136- 40.

13. Huang CY, Tseng KC, Lin MN, Tsai JP, Su CC. Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies. J Clin Pathol 2015; 68: 917-22.

14. Daniele A, Abbate I, Oakley C, Casamassima P, Savino E, Casamassima A, Sciortino G, et al. Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. Int J Biochem Cell Biol 2016; 77: 91-101.

15. Thrailkill K, Cockrell G, Simpson P, Moreau C, Fowlkes J, Bunn RC. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med 2006; 44: 503-4.